- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04650048
Modulation of an Experimental Prolonged Pain Model Using High Definition Transcranial Direct Current Stimulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this double-blinded, parallel group randomized controlled trial is to investigate the effects of high definition transcranial direct current stimulation (HD-tDCS) on an experimental prolonged pain model in healthy subjects. Forty healthy participants are administered the compound Nerve Growth Factor (NGF) in the right first dorsal interosseous muscle (FDI), which produced prolonged muscle soreness and hyperalgesia.
The forty participants are randomly allocated to either the control group receiving a Sham-tDCS paradigm, or the intervention group receiving three consecutive days of multimodal HD-tDCS targeting primary motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC) simultaneously.
The somatosensory profile is assessed at baseline, before administration of NGF as well as prior and post each HD-tDCS session using standardised quantitative sensory testing.
It is hypothesised that the active HD-tDCS will modulate the neurological changes induced by the experimental pain condition, which will alleviate the hyperalgesia and hypersensitivity.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sebastian Kold, MSc
- Phone Number: +4522850345
- Email: sks@hst.aau.dk
Study Locations
-
-
Nordjylland
-
Aalborg, Nordjylland, Denmark, 9000
- Recruiting
- Center for Neuroplasticity and Pain
-
Contact:
- Thomas Graven-Nielsen, Prof.
- Phone Number: +45 2216 049
- Email: tgn@hst.aau.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men and women.
- Able to speak, read and understand English or Danish.
Exclusion Criteria:
- Pregnancy
- Drug addiction defined as the use of cannabis, opioids or other drugs
- Current use of opioids, antipsychotics, benzodiazepines
- Previous or current neurological, musculoskeletal, rheumatic, malignant, inflammatory or mental illnesses
- Current or prior chronic pain conditions
- Lack of ability to cooperate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Active tDCS
Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention.
This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
|
Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
|
PLACEBO_COMPARATOR: Sham tDCS
Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention.
This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
|
Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This sham-configuration is intended to mimic the sensory experience of active HD-tDCS. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pressure pain threshold.
Time Frame: Six assessments over three days: Baseline is assessed before any intervention at day one, and then the pain thresholds are assessed before and after each intervention on the subsequent two days.
|
A hand-held pressure algometer (Somedic, Hörby, Sweden) with a 1-cm2 probe will be used to record the pressure pain threshold.
The pressure is increased gradually at a rate of 20 kPa/s.
The measurement is repeated three times on the first dorsal interosseous muscle.
|
Six assessments over three days: Baseline is assessed before any intervention at day one, and then the pain thresholds are assessed before and after each intervention on the subsequent two days.
|
Change in pressure pain tolerance.
Time Frame: Six assessments over three days: Baseline is assessed before any intervention at day one, and then the pain thresholds are assessed before and after each intervention on the subsequent two days.
|
A hand-held pressure algometer (Somedic, Hörby, Sweden) with a 1-cm2 probe will be used to record the pressure pain threshold at baseline.
The pressure is increased gradually at a rate of 20 kPa/s.
The measurement is repeated three times on the first dorsal interosseous muscle.
The participant is asked to rate the pain on a numerical rating scale (NRS) from 0-10.
0 representing no pain at all, and 10 representing the worst pain imaginable.
|
Six assessments over three days: Baseline is assessed before any intervention at day one, and then the pain thresholds are assessed before and after each intervention on the subsequent two days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in tactile detection threshold
Time Frame: Six assessments over three days: Baseline is assessed before any intervention at day one, and then the sensory thresholds are assessed before and after each intervention on the subsequent two days.
|
Tactile threshold will be measured using an anaesthesiometer consisting of a set of Von Frey filaments.
The filaments are made of nylon fibre of various diameters so as to provide a range of forces of up to 300 grams.
The minimum force that the subject can detect will be identified.
This will be assessed on flexor carpi radialis on the right hand arm.
|
Six assessments over three days: Baseline is assessed before any intervention at day one, and then the sensory thresholds are assessed before and after each intervention on the subsequent two days.
|
Change in mechanical pain threshold
Time Frame: Six assessments over three days: Baseline is assessed before any intervention at day one, and then the sensory thresholds are assessed before and after each intervention on the subsequent two days.
|
Mechanical pain threshold (MPT) will be measured using a set of weighted pinprick stimulators with a flat contact area of 0.25 mm diameter that exert forces between 8 and 512 mN.
Threshold procedures will use a method of limits with up to five series of ascending and descending stimulus intensities.
This will be assessed on flexor carpi radialis on the right hand arm.
|
Six assessments over three days: Baseline is assessed before any intervention at day one, and then the sensory thresholds are assessed before and after each intervention on the subsequent two days.
|
Change in conditioned pain modulation (CPM)
Time Frame: Three assessments over three days: Baseline is assessed before the stimulation at day one, and then again after the stimulation on the two subsequent days.
|
A computer-controlled cuff pressure algometer (Nocitech, Denmark) with an air-filled tourniquet cuff (VBM, Germany) will be used to record cuff pressure-induced pain thresholds over the muscle bulk on the calfs. The pressure is increased gradually at a rate of 1 kPa/s to assess pain tolerance on a 0-10 VAS scale, where 0 is no pain at all and 10 is the worst pain imaginable. During CPM testing, the pain tolerance is first assessed on one leg marking the baseline. The pressure pain tolerance is then assessed on the same leg again, while the contralateral calf is applied a simultaneous painful pressure stimulus. The outcome of the CPM testing is the difference in pressure pain tolerance measured in kPA between the first and the second assessment. The larger the positive difference is between the baseline and the second assessment, the stronger CPM effect the subject has. |
Three assessments over three days: Baseline is assessed before the stimulation at day one, and then again after the stimulation on the two subsequent days.
|
Change in temporal summation of pain (TSP).
Time Frame: Three assessments over three days: Baseline is assessed before the stimulation at day one, and then again after the stimulation on the two subsequent days.
|
TSP will be applied using cuff pressure algometry.
A total of 10 repeated mechanical pressure stimuli will be delivered at 0.5 Hz (1-s stimuli duration and 1-s interval between stimuli) to the test area.
During the 10 repeated stimuli, subjects will continuously rate the pain intensity on a 10-cm continuous VAS.
TSP is assessed on the calf of the right leg.
|
Three assessments over three days: Baseline is assessed before the stimulation at day one, and then again after the stimulation on the two subsequent days.
|
Change in electroencephalography response (EEG).
Time Frame: Three assessments over three days: The EEG will be recorded as a part of the HD-tDCS intervention.
|
EEG will be recorded for four minutes prior to the HD-tDCS, during the HD-tDCS and four minutes immediately after the HD-tDCS. In the four minutes before and after HD-tDCS, the subject will have their eyes open for two minutes and their eyes closed for two minutes. The EEG data will be analyzed with a focus on the resting state. In particular the Alpha frequency brain waves are of interest, but exploratory analysis will be conducted on the Beta, Theta and Gamma frequency bands as well. |
Three assessments over three days: The EEG will be recorded as a part of the HD-tDCS intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas Graven-Nielsen, Prof., Aalborg University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20180085.p2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Active HD-tDCS
-
The University of Texas at DallasCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Completed
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)Active, not recruitingMajor Depressive DisorderUnited States
-
Federal University of ParaíbaUniversity of Michigan; Rio de Janeiro State University; City University of New...RecruitingCoronavirus | COVID-19 Respiratory InfectionBrazil
-
Bambino Gesù Hospital and Research InstituteRecruitingDevelopmental DyslexiaItaly
-
University of MichiganNational Institute of Dental and Craniofacial Research (NIDCR)TerminatedTemporomandibular DisorderUnited States
-
University of MichiganCompleted
-
University of MichiganNational Institute of Mental Health (NIMH)Completed
-
Suellen AndradeCity University of New YorkCompletedCOVID-19 | Delirium | Critical IllnessBrazil
-
Suellen Marinho AndradeRecruitingCOVID-19 | Coronavirus | Inspiratory Muscle Training | Respiratory InfectionBrazil